PB2229: A PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF BENRALIZUMAB IN PATIENTS WITH HYPEREOSINOPHILIC SYNDROME

• Princess Ogbogu,
• Amy Klion,
• Florence Roufosse,
• Praveen Akuthota,
• Paneez Khoury,
• Vivian Shih,
• Dianne Griffis,
• Himanshu Parikh,
• Ron Chen,
• Ying Fan,
• Gaell Mayer,
• Priya Jain,
• Rohit Katial,
• Ioannis Psallidas

Affiliations

Princess Ogbogu

1 University Hospitals Rainbow Babies and Children’s Hospital, Department of Pediatrics, Cleveland, United States

Amy Klion

2 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Infectious Disease Specialist, Bethesda, United States

Florence Roufosse

3 Hôpital Erasme, Université Libre de Bruxelles, Internal Medicine, Brussels, Belgium

Praveen Akuthota

4 University of California San Diego, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, La Jolla, United States

Paneez Khoury

5 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Senior Clinician, Bethesda, United States

Vivian Shih

6 AstraZeneca, BioPharmaceuticals Medical, Gaithersburg, United States

Dianne Griffis

7 AstraZeneca, Late-Stage Development, Respiratory and Immunology, Durham, United States

Himanshu Parikh

8 AstraZeneca, Late-Stage Development, Respiratory and Immunology, Gaithersburg, United States

Ron Chen

9 AstraZeneca, Early Respiratory and Immunology, Cambridge, United Kingdom

Ying Fan

10 AstraZeneca, BioPharmaceuticals Medical, Gaithersburg, United States

Gaell Mayer

11 AstraZeneca, Late-Stage Development, Respiratory and Immunology, Gothenburg, Sweden

Priya Jain

12 AstraZeneca, Senior Global Medical Affairs Lead, Respiratory & Immunology, Cambridge, United Kingdom

Rohit Katial

6 AstraZeneca, BioPharmaceuticals Medical, Gaithersburg, United States

Ioannis Psallidas

13 AstraZeneca, Late-Stage Development, Respiratory and Immunology, Cambridge, United Kingdom